Additionally, SIRT2 increases the activity of Phosphoenolpyruvate Carboxykinase 1 (PEPCK1) and Glutaminase (GLS), which promote the metabolism of glycolysis and inhibit the E-cadherin pathway, which promotes the invasion of liver cancer cells16. Here, PCK1 is linked to liver cancer.